Biotest AG is a DE-based company operating in Biotechnology industry. The company is headquartered in Dreieich, Hessen and currently employs 2,495 full-time employees. Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology, and intensive care medicine. The company develops, manufactures, and markets immunoglobulin, coagulation factors, and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.
Based on comprehensive analyst evaluations, we have synthesized critical insights from expert assessments to outline a cautious outlook for BIESF. Analysts note deteriorating fundamentals and challenging market sentiment, indicating potential downside risks in the near term. Following this expert analysis, we adopt a bearish stance on this stock. Our conclusion: BIESF is a Sell candidate.
BIESF stock price ended at $32 on 月曜日, after dropping NaN%
On the latest trading day Mar 10, 2025, the stock price of BIESF fell by NaN%, dropping from $32.00 to $32.00. During the session, the stock saw a volatility of 0.00%, with prices oscillating between a daily low of $32.00 and a high of $32.00. On the latest trading day, the trading volume for BIESF decreased by -- shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 100 shares were traded, with a market value of approximately $633.1M.